Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-07-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose of pembrolizumab and binimetinib and how well it
works when given together with pembrolizumab in treating patients with triple negative breast
cancer that has spread to other parts of the body (metastatic). Immunotherapy with monoclonal
antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Binimetinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
pembrolizumab and binimetinib may work better in treating patients with triple negative
breast cancer.